Synthesis and biological evaluation of novel quinoxalinone-based HIV-1 reverse transcriptase inhibitors

Med. Chem. Commun.
2013.0

Abstract

A series of novel 6-chloro-3-methyl-3,4-dihydroquinoxalin-2(1H)-ones bearing a 2,5-disubstituted thiophen-3-ylsulfonyl moiety were designed and synthesized aiming to improve the anti-HIV-1 activity of quinoxalinone derivatives. The target compounds were synthesized via microwave irradiation, Suzuki coupling and other reactions by modifying the 2- and 5-positions of the thiophene ring. Their anti-HIV-1 replication activities were evaluated using a cell-based model, and molecular docking with CDOCKER was performed to analyze the structure-activity relationships (SAR). Compounds 1b (with 5-chloro-2-methoxycarbonyl thiophene fragment) and 1d (with 5-iodo-2-methoxycarbonyl thiophene fragment) were identified as the most potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) with IC50 values at the 10⁻⁸ mol/L level. SAR analysis showed that halogen substituents (chloro, iodo) at the 5-position of the thiophene ring were favorable for activity, while bulky aromatic groups or hydrophilic substituents (e.g., carboxylic, hydroxymethyl, aldehyde) reduced activity. However, none of the tested compounds effectively inhibited the HIVRT-K103N and HIVRT-Y181C resistant strains. In summary, these quinoxalinone derivatives are potential NNRTIs, and the SAR results will facilitate the further development of novel potent quinoxaline-based NNRTIs.

Knowledge Graph

Similar Paper

Synthesis and biological evaluation of novel quinoxalinone-based HIV-1 reverse transcriptase inhibitors
Med. Chem. Commun. 2013.0
Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors
Bioorganic & Medicinal Chemistry 2009.0
Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme
European Journal of Medicinal Chemistry 2020.0
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
Bioorganic & Medicinal Chemistry 2011.0
Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors
Bioorganic & Medicinal Chemistry 2014.0
2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5
European Journal of Medicinal Chemistry 2016.0
Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors
Bioorganic & Medicinal Chemistry Letters 2006.0
Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors
European Journal of Medicinal Chemistry 2018.0
Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives
Bioorganic & Medicinal Chemistry 2020.0
Quinoxalinylethylpyridylthioureas (QXPTs) as Potent Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors. Further SAR Studies and Identification of a Novel Orally Bioavailable Hydrazine-Based Antiviral Agent
Journal of Medicinal Chemistry 2001.0